naltrexone has been researched along with Disease Exacerbation in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Bonilla, A; Bonilla, H; Eggert, L; Geng, LN; Marconi, VC; McComsey, GA; Miglis, M; Shafer, R; Tian, L; Yang, P | 1 |
| Feng, Y; Liu, N; Ma, M; Shan, F; Wang, X | 1 |
| Anton, RF; Baker, NL; Bandyopadhyay, D; DeSantis, SM; Prisciandaro, JJ; Randall, PK | 1 |
| Donahue, RN; McLaughlin, PJ; Zagon, IS | 1 |
| Battisti, JJ; Forman, R; Gastfriend, DR; Pettinati, HM; Schweizer, E; Silverman, BL | 1 |
| Bisaga, A; Carpenter, KM; Cheng, WY; Levin, FR; Mariani, JJ; Nunes, EV; Raby, WN; Sullivan, MA | 1 |
| O'Brien, CP | 1 |
1 review(s) available for naltrexone and Disease Exacerbation
| Article | Year |
|---|---|
Research advances in the understanding and treatment of addiction.
Topics: Acamprosate; Alcohol Deterrents; Brain; Chronic Disease; Disease Progression; Humans; Naltrexone; Narcotics; Prognosis; Recurrence; Risk Factors; Substance-Related Disorders; Taurine | 2003 |
3 trial(s) available for naltrexone and Disease Exacerbation
| Article | Year |
|---|---|
Modeling longitudinal drinking data in clinical trials: an application to the COMBINE study.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Cognitive Behavioral Therapy; Combined Modality Therapy; Data Interpretation, Statistical; Disease Progression; Female; Humans; Longitudinal Studies; Male; Models, Statistical; Naltrexone; Narcotic Antagonists; Poisson Distribution; Risk-Taking; Taurine; Temperance; Treatment Outcome | 2013 |
Efficacy of extended-release naltrexone in patients with relatively higher severity of alcohol dependence.
Topics: Adult; Alcohol Drinking; Alcoholism; Cognitive Behavioral Therapy; Delayed-Action Preparations; Disease Progression; Double-Blind Method; Female; Humans; Injections; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Patient Compliance; Psychiatric Status Rating Scales; Temperance; Time Factors; Treatment Outcome | 2011 |
A placebo controlled trial of memantine as an adjunct to oral naltrexone for opioid dependence.
Topics: Adult; Disease Progression; Dopamine Agents; Double-Blind Method; Female; Humans; Male; Medication Adherence; Memantine; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Placebos; Receptors, N-Methyl-D-Aspartate; Secondary Prevention; Substance Abuse Detection; Substance Withdrawal Syndrome; Time Factors; Treatment Outcome; Young Adult | 2011 |
3 other study(ies) available for naltrexone and Disease Exacerbation
| Article | Year |
|---|---|
Low-dose naltrexone use for the management of post-acute sequelae of COVID-19.
Topics: COVID-19; Disease Progression; Humans; Naltrexone; Post-Acute COVID-19 Syndrome; SARS-CoV-2 | 2023 |
Low-dose naltrexone inhibits colorectal cancer progression and promotes apoptosis by increasing M1-type macrophages and activating the Bax/Bcl-2/caspase-3/PARP pathway.
Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Carcinogenesis; Caspase 3; Cell Differentiation; Colorectal Neoplasms; Cytokines; Disease Progression; Gene Expression Regulation, Neoplastic; HCT116 Cells; Humans; Macrophages; Mice; Mice, Nude; Naltrexone; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-bcl-2; Receptors, Opioid; Signal Transduction; Th1 Cells | 2020 |
The opioid growth factor (OGF) and low dose naltrexone (LDN) suppress human ovarian cancer progression in mice.
Topics: Animals; Apoptosis; Cell Line, Tumor; Disease Progression; DNA; Enkephalin, Methionine; Female; Humans; Mice; Mice, Nude; Naltrexone; Narcotic Antagonists; Neovascularization, Pathologic; Ovarian Neoplasms; Receptors, Opioid; Xenograft Model Antitumor Assays | 2011 |